You Position: Home > Paper
Recent advances in molecular targeted therapy of hepatocellular carcinoma
( views:13, downloads:0 )
- Author:
- No author available
- Journal Title:
- World Chinese Journal of Digestology
- Issue:
- 34
- DOI:
- 10.11569/wcjd.v26.i34.2008
- Key Word:
- 肝细胞癌;分子机制;靶向治疗;靶向药物
Abstract： 肝细胞癌(hepatocellular carcinoma,HCC)死亡率居所有肿瘤的第二位,且近年在我国有上升趋势.因其发病隐匿、进展快、预后差,一直是研究的热点和难点.近10年来,HCC的治疗方法有了显著性进展,尤其是分子靶向药物的使用和研究,开启了HCC治疗方法的新阶段.本文就目前HCC发生发展相关信号通路及潜在分子靶点的研究现状、分子靶向治疗药物临床使用状况以及新药研发进展做了比较详细地叙述.
- [1]Duffy, Austin G.,Ulahannan, Susanna V.,Makorova-Rusher, Oxana,etc.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J].2017,66(3).
- [2]Hanahan, D.,Weinberg, R.A..Hallmarks of cancer: The next generation[J].2011,144(5).
- [3]Gadaleta-Caldarola, Gennaro,Infusino, Stefania,Divella, Rosa,etc.Sorafenib: 10 years after the first pivotal trial[J].2015,11(13).
- [4]Goyal,L.,Muzumdar,M.D.,Zhu,A.X..Targeting the HGF/c-MET pathway in hepatocellular carcinoma[J].2013,19(9).
- [5]Tobias, Engl,Jochen, Rutz,Sebastian, Maxeiner,etc.mTOR inhibition reduces growth and adhesion of hepatocellular carcinoma cells in?vitro.[J].2017,16(5).
- [6]Sullivan DM,Lush RM,Kazi A,etc.Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.[J].2011,29(17).
- [7]Ghassan K, Abou-Alfa,Philip, Johnson,Jennifer J, Knox,etc.Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.[J].2010,304(19).
- [8]Ikeda, Kenji,Kudo, Masatoshi,Kawazoe, Seiji,etc.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma[J].2017,52(4).
- [9]Zhu AX,Abrams TA,Miksad R,etc.Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.[J].2011,117(22).
- [10]Kallender, Howard,Cox, Donna S.,Adams, Laurel M.,etc.Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors[J].2015,55(10).
- [11]Yasushi Totoki,Kenji Tatsuno,Kyle R Covington,etc.Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.[J].2014,46(12).
- [12].The Cancer Immunotherapy Revolution.[J].2018,359(6382).
- [13].Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification[J].2014,60(6).
- [14]Grimber G,Elie C,Letourneur F,etc.Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations.[J].2007,212(3).
- [15]Llovet JM,Ricci S,Mazzaferro V,etc.Sorafenib in advanced hepatocellular carcinoma.[J].2008,359(4).
- [16]Llovet, Josep M.,Villanueva, Augusto,Lachenmayer, Anja,etc.Advances in targeted therapies for hepatocellular carcinoma in the genomic era[J].2015,12(7).
- [17]Roviello, Giandomenico,Ravelli, Andrea,Polom, Karol,etc.Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer[J].2016,372(2).
- [18]Dashzeveg, Nurmaa,Yoshida, Kiyotsugu.Cell death decision by p53 via control of the mitochondrial membrane[J].2015,367(2).
- [19]Tai, W. M.,Yong, W. P.,Lim, C.,etc.A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)[J].2016,27(12).
- [20].EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J].2018,69(1).